Karl J. Krobot

1.6k total citations
32 papers, 1.2k citations indexed

About

Karl J. Krobot is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Karl J. Krobot has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 8 papers in Cardiology and Cardiovascular Medicine and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Karl J. Krobot's work include Lipoproteins and Cardiovascular Health (7 papers), Health and Medical Studies (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Karl J. Krobot is often cited by papers focused on Lipoproteins and Cardiovascular Health (7 papers), Health and Medical Studies (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Karl J. Krobot collaborates with scholars based in United States, Germany and Spain. Karl J. Krobot's co-authors include Hans‐Werner Hense, Peter Cremer, U Keil, Oliver Schöffski, Peter L. Kolominsky‐Rabas, Martin Emmert, B. Neundörfer, Peter U. Heuschmann, Dangyue Yin and K Wenke and has published in prestigious journals such as Circulation, Clinical Infectious Diseases and Stroke.

In The Last Decade

Karl J. Krobot

32 papers receiving 1.2k citations

Peers

Countries citing papers authored by Karl J. Krobot

Since Specialization

Citations

This map shows the geographic impact of Karl J. Krobot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl J. Krobot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl J. Krobot more than expected).

Fields of papers citing papers by Karl J. Krobot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl J. Krobot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl J. Krobot. The network helps show where Karl J. Krobot may publish in the future.

Co-authorship network of co-authors of Karl J. Krobot

This figure shows the co-authorship network connecting the top 25 collaborators of Karl J. Krobot. A scholar is included among the top collaborators of Karl J. Krobot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl J. Krobot. Karl J. Krobot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PIN40 Cost-Effectiveness of Boceprevir-Based Treatment of Chronic Genotype 1 Hepatitis C Virus (HCV) Infection From the Perspective of the German Statutory Health Insurance (SHI) 2012 ·Value in Health ·Benedikt Becker, Jagpreet Chhatwal, Shannon Ferrante, Elamin H. Elbasha, Karl J. Krobot	1
2	Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA_1cvalue 2012 ·Current Medical Research and Opinion ·Karl J. Krobot, Shannon Ferrante, Michael J. Davies, Thomas Seck, Gary Meininger, Debora Williams‐Herman, Keith D. Kaufman, Barry J. Goldstein	14
3	Cost of clinical events in health economic evaluations in Germany: a systematic review 2012 ·Cost Effectiveness and Resource Allocation ·M Scheuringer, (unknown), Karl J. Krobot, Volker Ulrich	7
4	Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry 2012 ·European journal of medical research ·Gerlinde Egerer, Dietmar Reichert, Mathias W. Pletz, Peter Kaskel, Karl J. Krobot, Johan Maertens	10
5	Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany 2011 ·The European Journal of Health Economics ·G. Michailov, Glenn Davies, Karl J. Krobot	8
6	Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial 2010 ·Diabetes Obesity and Metabolism ·(unknown), Thomas Seck, Yong Chen, Karl J. Krobot, Edward A. O’Neill, (unknown), Keith D. Kaufman, Debora Williams‐Herman, B. J. Goldstein	136
7	Caspofungin nach Transplantation solider Organe in Deutschland 2010 ·Der Anaesthesist ·Christoph Lichtenstern, Johann Pratschke, Uwe Schulz, Michael Schmoeckel, Wolfgang Knitsch, Peter Kaskel, Karl J. Krobot, M. A. Weigand, (unknown)	3
8	Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes 2009 ·Health and Quality of Life Outcomes ·Tom Stargardt, Linda Gonder‐Frederick, Karl J. Krobot, Charles M. Alexander	54
9	Blood pressure control in the year following coronary events 2007 ·International Journal of Cardiology ·Jacqueline Müller‐Nordhorn, Heinz Völler, Andrea Pfennig, Sylvia Binting, Karl J. Krobot, Stefan N. Willich	2
10	Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany 2006 ·European Journal of Cancer ·Florian Lordick, B. Ehlken, Angela Ihbe‐Heffinger, Karin Berger, Karl J. Krobot, James M. Pellissier, Glenn Davies, Robert Deuson	41
11	Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries 2006 ·Clinical Infectious Diseases ·Andrew J. Ullmann, Miguel Á. Sanz, Andrea Tramarin, R.A. Barnes, Weizhou Wu, B. Gerlach, Karl J. Krobot, (unknown), (unknown)	78
12	Regional variation in medication following coronary events in Germany 2004 ·International Journal of Cardiology ·Jacqueline Müller‐Nordhorn, Michael Kulig, Sylvia Binting, Heinz Völler, Karl J. Krobot, Stefan N. Willich	6
13	Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal 2004 ·PharmacoEconomics ·J.R. Cook, (unknown), E. Alemao, Glenn Davies, Karl J. Krobot, Enrico P. Veltri, Leslie Lipka, Xavier Badı́a	21
14	The Disparity in Access to New Medication by Type of Health Insurance 2004 ·Medical Care ·Karl J. Krobot, William C. Miller, Jay S. Kaufman, Dale B. Christensen, John S. Preisser, Michel Ibrahim	33
15	Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery 2004 ·European Journal of Clinical Microbiology & Infectious Diseases ·Karl J. Krobot, Dangyue Yin, Q. Zhang, Saugata Sen, A. Altendorf-Hofmann, J. Scheele, Wolfgang Sendt	117
16	Quantifying Delay in Access to New Medical Treatment 2004 ·Epidemiology ·Karl J. Krobot, William C. Miller, Jay S. Kaufman, Dale B. Christensen, John S. Preisser, Michel Ibrahim	1
17	Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 2004 ·Journal of Human Hypertension ·(unknown), Thomas Burke, Karl J. Krobot, George W. Carides, Jonathan M. Edelman, Richard B. Devereux, HC Diener	41
18	Simvastatin Initiated Early After Heart Transplantation 2003 ·Circulation ·K Wenke, Bruno Meiser, Joachim Thiery, Dorothea Nagel, Wolfgang von Scheidt, Karl J. Krobot, Gerhard Steinbeck, D. Seidel, Bruno Reichart	173
19	Outpatient costs of osteoporosis in a national health insurance population 1999 ·Clinical Therapeutics ·Jutta Krappweis, Anke Rentsch, Ute I. Schwarz, Karl J. Krobot, Wilhelm Kirch	12
20	Simvastatin After Orthotopic Heart Transplantation 1999 ·PharmacoEconomics ·Karl J. Krobot, K Wenke, Bruno Reichart	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact